Dual PDE4/7 inhibitors may have a potential in the treatment of TH1 mediated autoimmune diseases like Multiple Sclerosis, Rheumatoid Arthritis, and Psoriasis etc. The gene discussed is PDE4A; the disease is autoimmune disease.